HPHA Stock Overview
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.83 |
| 52 Week High | €6.50 |
| 52 Week Low | €3.70 |
| Beta | -0.27 |
| 1 Month Change | -4.25% |
| 3 Month Change | -19.87% |
| 1 Year Change | -24.90% |
| 3 Year Change | -10.09% |
| 5 Year Change | 43.99% |
| Change since IPO | -92.76% |
Recent News & Updates
Recent updates
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14Shareholder Returns
| HPHA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.3% | 0.2% | 1.1% |
| 1Y | -24.9% | -7.6% | -7.0% |
Return vs Industry: HPHA underperformed the German Biotechs industry which returned -8% over the past year.
Return vs Market: HPHA underperformed the German Market which returned -7.6% over the past year.
Price Volatility
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: HPHA is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HPHA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 100 | Jan Schmidt-Brand | https://heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-XX for the treatment of solid/hematological tumors; MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; and TAK-ATACs for oncology.
Heidelberg Pharma AG Fundamentals Summary
| HPHA fundamental statistics | |
|---|---|
| Market Cap | €178.42m |
| Earnings (TTM) | -€19.02m |
| Revenue (TTM) | €20.00m |
8.9x
P/S Ratio-9.4x
P/E RatioIs HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPHA income statement (TTM) | |
|---|---|
| Revenue | €20.00m |
| Cost of Revenue | €5.50m |
| Gross Profit | €14.50m |
| Other Expenses | €33.52m |
| Earnings | -€19.02m |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
Jul 13, 2023
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 72.50% |
| Net Profit Margin | -95.11% |
| Debt/Equity Ratio | 17.0% |
How did HPHA perform over the long term?
See historical performance and comparison